 Context Therapeutics NASDAQ:CNTX Inc has announced a plan to streamline its resources and extend its cash runway into 2024 as market pressures put a strain on biotechnology companies. The womens oncology company plans to defer noncritical RD activities, reduce future overhead and infrastructure expenditures and push forward with its onapristone extended release ONA-XR ELONA Phase 1b2 clinical trial and Claudin 6 CLDN6 program. 